 | Up a level |
Fasshauer, Maria; Borte, Michael; Bitzenhofer, Michaela; Pausch, Christine; Pittrow, David; Park, Michelle; Gladiator, André; Jandus, Peter (2023). Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases. Advances in therapy, 40(12), pp. 5168-5187. Springer 10.1007/s12325-023-02649-0
Jandus, Peter; Bitzenhofer-Grüber, Michaela (2022). [Antibodydeficiencies Epidemiology, Clinical manifestation, Diagnostics and Therapy]. Therapeutische Umschau, 79(6), pp. 279-283. Hogrefe 10.1024/0040-5930/a001361
Bitzenhofer, Michaela; Suter-Riniker, Franziska; Moor, Matthias B; Sidler, Daniel; Horn, Michael P; Gschwend, Anna; Staehelin, Cornelia; Rauch, Andri; Helbling, Arthur; Jörg, Lukas (2022). Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease. PLoS ONE, 17(6), e0268780. Public Library of Science 10.1371/journal.pone.0268780
Marschall, K; Hoernes, M; Bitzenhofer-Grüber, Michaela Aphrodite; Jandus, P; Duppenthaler, Andrea; Wuillemin, Natascha Andrea; Rischewski, J; Boyman, O; Heininger, U; Hauser, T; Steiner, U; Posfay-Barbe, K; Seebach, J; Recher, M; Hess, C; Helbling, Arthur; Reichenbach, J (2015). The Swiss National Registry for Primary Immunodeficiencies: report on the first 6 years' activity from 2008 to 2014. Clinical and experimental immunology, 182(1), pp. 45-50. Blackwell Scientific Publications 10.1111/cei.12661
Fasshauer, Maria; Borte, Michael; Bitzenhofer, Michaela; Pausch, Christine; Pittrow, David; Park, Michelle; Gladiator, André; Jandus, Peter (2022). Real-world utilization, safety and patient experience of 20% subcutaneous immunoglobuin in patients with primary immunodeficiencies: final data from the core study (Unpublished). In: ESID Kongress Gothenburg 2022.
